Up‐regulation of NMDA receptor subunit and post‐synaptic density protein expression in the thalamus of elderly patients with schizophrenia

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Neurochemistry

• Publication date

  2006-08-01

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1111/j.1471-4159.2006.03954.xPMID 16762023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The limbic system

  2007cited by this paper
• Abnormal hemodynamics in schizophrenia during an auditory oddball task.

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• "Gamma synchrony" in first-episode schizophrenia: a disorder of temporal connectivity?

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder.

  2005cited by this paper
• Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

  2005cited by this paper
• Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin.

  2005cited by this paper
• Early-stage visual processing and cortical amplification deficits in schizophrenia.

  2005cited by this paper
• NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder.

  2004cited by this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cited by this paper
• Decreased Phosphorylation of NMDA Receptor Type 1 at Serine 897 in Brains of Patients with Schizophrenia

  2004cited by this paper
• Glutamate receptors as therapeutic targets

  2004cited by this paper
• An fMRI study of differential neural response to affective pictures in schizophrenia

  2004cited by this paper
• Thalamic dysfunction in schizophrenia: neurochemical, neuropathological, and in vivo imaging abnormalities.

  2004influential reference
• Neurofilament subunit protein abnormalities in the thalamus in schizophrenia

  2004cited by this paper
• Abnormalities of the NMDA Receptor and Associated Intracellular Molecules in the Thalamus in Schizophrenia and Bipolar Disorder

  2004influential reference
• Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: Volume, neuron number, and cell types

  2004cited by this paper
• Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia.

  2004cited by this paper
• Cycling of NMDA Receptors during Trafficking in Neurons before Synapse Formation

  2004cited by this paper
• The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders.

  2004cited by this paper
• KIF17 Dynamics and Regulation of NR2B Trafficking in Hippocampal Neurons

  2003cited by this paper
• Up-regulation of the D1 dopamine receptor-interacting protein, calcyon, in patients with schizophrenia.

  2003cited by this paper
• NMDA receptor trafficking through an interaction between PDZ proteins and the exocyst complex

  2003influential reference
• Volumes of association thalamic nuclei in schizophrenia: a postmortem study.

  2003cited by this paper
• Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia.

  2003influential reference
• Retention of NMDA receptor NR2 subunits in the lumen of endoplasmic reticulum in targeted NR1 knockout mice

  2003influential reference
• A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia.

  2003cited by this paper
• Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study.

  2002cited by this paper
• Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia.

  2002influential reference
• Subunit-specific NMDA receptor trafficking to synapses.

  2002cited by this paper
• NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity.

  2002cited by this paper
• The ventral lateral posterior nucleus of the thalamus in schizophrenia: a post-mortem study.

  2002cited by this paper
• Selective reduction of a PDZ protein, SAP‐97, in the prefrontal cortex of patients with chronic schizophrenia

  2002cited by this paper
• Magnetic resonance imaging of the thalamus in first-episode psychosis.

  2001cited by this paper
• Uncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptors alter the mRNA expression of proteins associated with the NMDA receptor complex.

  2001cited by this paper
• Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia

  2001influential reference
• Kainate-induced seizures alter protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic densities.

  2001cited by this paper
• N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia.

  2001cited by this paper
• The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

  2001cited by this paper
• Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia.

  2001influential reference
• An NMDA Receptor ER Retention Signal Regulated by Phosphorylation and Alternative Splicing

  2001cited by this paper
• Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder.

  2001cited by this paper
• Meta-analysis of thalamic size in schizophrenia.

  2001cited by this paper
• Receptor crosstalk protein, calcyon, regulates affinity state of dopamine D1 receptors.

  2001cited by this paper
• Alterations of Thalamic Activity in Schizophrenia and in Response to Antipsychotic Drugs

  2001cited by this paper
• Thalamic volumes in patients with first-episode schizophrenia.

  2001cited by this paper
• Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport.

  2000cited by this paper
• Ligand-gated ion channel interactions with cytoskeletal and signaling proteins.

  2000cited by this paper
• C-Terminal Truncation of NR2A Subunits Impairs Synaptic But Not Extrasynaptic Localization of NMDA Receptors

  2000cited by this paper
• PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants.

  2000cited by this paper
• Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia.

  2000cited by this paper
• Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia.

  2000cited by this paper
• Coexpression of Postsynaptic Density‐95 Protein with NMDA Receptors Results in Enhanced Receptor Expression Together with a Decreased Sensitivity to L‐Glutamate

  2000cited by this paper
• Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus.

  2000cited by this paper
• Dual signaling regulated by calcyon, a D1 dopamine receptor interacting protein.

  2000cited by this paper
• Subnucleus-specific loss of neurons in medial thalamus of schizophrenics.

  2000cited by this paper
• Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia.

  2000cited by this paper
• A magnetic resonance imaging study of thalamic area in adolescent patients with either schizophrenia or bipolar disorder as compared to healthy controls.

  1999cited by this paper
• Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum.

  1999cited by this paper
• Decreased hippocampal (CA3) NMDA receptors in schizophrenia

  1999cited by this paper
• NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia.

  1999cited by this paper
• NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders.

  1999cited by this paper
• Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia.

  1998cited by this paper
• Positron emission tomography studies of abnormal glucose metabolism in schizophrenia.

  1998cited by this paper
• Chapter I - The thalamus of primates

  1998cited by this paper
• Partial volume decrease of the thalamus in relatives of patients with schizophrenia.

  1998cited by this paper
• D-serine added to antipsychotics for the treatment of schizophrenia.

  1998cited by this paper
• Splice Variant-Specific Interaction of the NMDA Receptor Subunit NR1 with Neuronal Intermediate Filaments

  1998cited by this paper
• Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons.

  1998cited by this paper
• Assembly intracellular targeting and cell surface expression of the human N-methyl-D-aspartate receptor subunits NR1a and NR2A in transfected cells.

  1998cited by this paper
• Impaired recruitment of the hippocampus during conscious recollection in schizophrenia

  1998cited by this paper
• Interaction of the N-Methyl—aspartate Receptor Complex with a Novel Synapse-associated Protein, SAP102*

  1996cited by this paper
• SAP102, a novel postsynaptic protein that interacts with NMDA receptor complexes in vivo.

  1996cited by this paper
• The thalamus as a site of action of antipsychotic drugs.

  1996cited by this paper
• Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.

  1996cited by this paper
• PET and MRI of the thalamus in never-medicated patients with schizophrenia.

  1996cited by this paper
• Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry.

  1996cited by this paper
• Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

  1995cited by this paper
• Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action.

  1995cited by this paper
• Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia.

  1995cited by this paper
• D2-Family receptor distribution in human postmortem tissue: an autoradiographic study

  1995cited by this paper
• High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients.

  1995cited by this paper
• Ketamine activates psychosis and alters limbic blood flow in schizophrenia

  1995cited by this paper
• A functional neuroanatomy of hallucinations in schizophrenia

  1995cited by this paper
• Amelioration of negative symptoms in schizophrenia by glycine.

  1994cited by this paper
• Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging.

  1994cited by this paper
• Cloned glutamate receptors.

  1994cited by this paper
• Leucotomized schizophrenics lose neurons in the mediodorsal thalamic nucleus

  1993cited by this paper
• Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex.

  1993cited by this paper
• Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.

  1992cited by this paper
• The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics.

  1992cited by this paper
• Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics.

  1990cited by this paper
• Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities.

  1990cited by this paper
• A new parcellation of the human thalamus on the basis of histochemical staining.

  1989cited by this paper
• Positron emission tomography and subcortical glucose metabolism in schizophrenia.

  1988cited by this paper
• Atlas of the human brain

  1979cited by this paper

• Serum NR1 and NR2 concentrations in first-episode schizophrenia and clinical high-risk for psychosis

  2025cites this paper
• Multifaceted roles of DLG3/SAP102 in neurophysiology, neurological disorders and tumorigenesis.

  2024cites this paper
• Long-term effects of a double hit murine model for schizophrenia on parvalbumin expressing cells and plasticity-related molecules in the thalamic reticular nucleus and the habenula

  2024cites this paper
• Unveiling Functional Biomarkers in Schizophrenia: Insights from Region of Interest Analysis Using Machine Learning.

  2024cites this paper
• Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics’ Treatment of Schizophrenia

  2022cites this paper
• Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia

  2020cites this paper
• NMDA Receptor Model of Antipsychotic Drug-Induced Hypofrontality

  2019cites this paper
• Synapse Pathology in Schizophrenia: A Meta-analysis of Postsynaptic Elements in Postmortem Brain Studies

  2019cites this paper
• Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

  2018cites this paper
• Effects of neonatal excitotoxic lesions in ventral thalamus on social interaction in the rat

  2018cites this paper
• Pervasive chromatin remodeling at X-inactivation escape genes in schizophrenic males

  2018cites this paper
• Novel rare variations in genes that regulate developmental change in N-methyl-d-aspartate receptor in patients with schizophrenia

  2018cites this paper
• Extended neuroleptic administration affects the NMDAR subunits immunoexpression in the rat diencephalon and neocortex

  2016cites this paper
• PSD-95 regulates CRFR1 localization, trafficking and β-arrestin2 recruitment.

  2016cites this paper
• Extended neuroleptic administration modulates NMDA-R subunit immunoexpression in the rat neocortex and diencephalon

  2016cites this paper
• Molecular evidence of synaptic pathology in the CA1 region in schizophrenia

  2016cites this paper
• The PSD: A Microdomain for Converging Molecular Abnormalities in Schizophrenia

  2016cites this paper
• The use of adjuvant L-arginine in schizophrenia: A behavioural and neurochemical analysis

  2016cites this paper
• Molecular evidence for decreased synaptic efficacy in the postmortem olfactory bulb of individuals with schizophrenia.

  2015cites this paper
• Combined effect of genetic variants in the GluN2B coding gene (GRIN2B) on prefrontal function during working memory performance

  2015cites this paper
• Influence of Genetic Variants of the N-Methyl-D-Aspartate Receptor on Emotion and Social Behavior in Adolescents

  2015cites this paper
• Specific Roles of NMDA Receptor Subunits in Mental Disorders

  2015cites this paper
• Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia.

  2015cites this paper
• NR2B or not 2B? Alterations of NR2B in schizophrenia and the effect of an NR2B blockade in an exploratory mouse model. Is there a link between NR2B and schizophrenia pathology?

  2015cites this paper
• The Role of Nitric Oxide and Nitrosative Stress in Schizophrenia

  2015cites this paper
• The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies

  2015cites this paper
• Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia

  2015cites this paper
• Glutamatergic Postsynaptic Density Protein Dysfunctions in Synaptic Plasticity and Dendritic Spines Morphology: Relevance to Schizophrenia and Other Behavioral Disorders Pathophysiology, and Implications for Novel Therapeutic Approaches

  2014cites this paper
• MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine–Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective

  2014cites this paper
• Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau₄₅₋₂₃₀ transgenic mice.

  2014cites this paper
• Regulation of CRFR1 and 5-HT2AR by PDZ Domain-Containing Proteins SAP97 and PSD-95

  2014cites this paper
• The role of kynurenine metabolism in the development of the central nervous system

  2014cites this paper
• Postmortem Brain: An Underutilized Substrate for Studying Severe Mental Illness

  2014cites this paper
• The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment

  2014cites this paper
• Increased Glutamate Receptor and Transporter Expression in the Cerebral Cortex and Striatum of Gcdh -/- Mice: Possible Implications for the Neuropathology of Glutaric Acidemia Type I

  2014cites this paper
• NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia

  2013cites this paper
• N-Methyl-d-Aspartate Receptor – Nitric Oxide Synthase Pathway in the Cortex of Nogo-A-Deficient Rats in Relation to Brain Laterality and Schizophrenia

  2013cites this paper
• Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments

  2012influential citation
• Contributions of the D-serine pathway to schizophrenia.

  2012cites this paper
• Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.

  2012cites this paper
• Regional differences in expression of β-tubulin isoforms in schizophrenia.

  2012cites this paper
• Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia.

  2011cites this paper
• Glutamatergic Neurotransmission Abnormalities and Schizophrenia

  2011cites this paper
• Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.

  2011cites this paper
• Genetic and Functional Analysis of the DLG4 Gene Encoding the Post-Synaptic Density Protein 95 in Schizophrenia

  2010cites this paper
• Role of the NMDA receptor subunit, NR3A, in glutamatergic synapse development

  2010cites this paper
• esearch report-methyl-d-aspartate ( NMDA ) receptor dysfunction or dysregulation : The final ommon pathway on the road to schizophrenia ?

  2010cites this paper
• Expression of NR1 subunit of NMDA receptor and PSD-93/95 in rat hippocampus affected by NR1/NR2 antisense oligodeoxynucleotide

  2010cites this paper
• The thalamus and schizophrenia: current status of research

  2009cites this paper
• Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies

  2009cites this paper
• Behavioural and chemical changes induced by early brain development interruption from PCP : implications for schizophrenia

  2009cites this paper
• Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade.

  2009cites this paper
• Schizophrenia; from structure to function with special focus on the mediodorsal thalamic prefrontal loop

  2009cites this paper
• Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review

  2008influential citation
• Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

  2008cites this paper
• Developmental regulation of the NMDA receptor subunits, NR3A and NR1, in human prefrontal cortex.

  2008cites this paper
• Ionotropic glutamate receptor mRNA expression in the human thalamus: absence of change in schizophrenia.

  2008cites this paper
• Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei.

  2008cites this paper
• Potential role of adenosine A2A receptors in the treatment of schizophrenia.

  2008cites this paper
• The Role of Astrocytes in the Pathophysiology of Schizophrenia.

  2007cites this paper
• An organelle proteomic method to study neurotransmission‐related proteins, applied to a neurodevelopmental model of schizophrenia

  2007cites this paper
• The Role of Astrocytes in the Pathophysiology of Schizophrenia.

  2007cites this paper
• Post‐synaptic density perturbs insulin‐induced Kv1.3 channel modulation via a clustering mechanism involving the SH3 domain

  2007cites this paper
• NMDA receptors and schizophrenia.

  2007cites this paper